minocycline and Optic-Atrophy--Hereditary--Leber

minocycline has been researched along with Optic-Atrophy--Hereditary--Leber* in 1 studies

Other Studies

1 other study(ies) available for minocycline and Optic-Atrophy--Hereditary--Leber

ArticleYear
Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation.
    Neurobiology of disease, 2007, Volume: 28, Issue:3

    Leber's hereditary optic neuropathy (LHON) is a retinal neurodegenerative disorder caused by mitochondrial DNA point mutations. Complex I of the respiratory chain affected by the mutation results in a decrease in ATP and an increase of reactive oxygen species production. Evaluating the efficacy of minocycline in LHON, the drug increased the survival of cybrid cells in contrast to the parental cells after thapsigargin-induced calcium overload. Similar protection was observed by treatment with cyclosporine A, a blocker of the mitochondrial permeability transition pore (mPTP). Ratiometric Ca(2+) imaging reveals that acetylcholine/thapsigargin triggered elevation of the cytosolic calcium concentration is alleviated by minocycline and cyclosporine A. The mitochondrial membrane potential of LHON cybrids was significantly conserved and the active-caspase-3/procaspase-3 ratio was decreased in both treatments. Our observations show that minocycline inhibits permeability transition induced by thapsigargin in addition to its antioxidant effects. In relation with its high safety profile, these results would suggest minocycline as a promising neuroprotective agent in LHON.

    Topics: Acetylcholine; Analysis of Variance; Calcium; Cell Death; Cholinergic Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Hybrid Cells; Hydrogen Peroxide; Membrane Potential, Mitochondrial; Minocycline; Mutation; Neuroprotective Agents; Optic Atrophy, Hereditary, Leber; Thapsigargin; Time Factors

2007